• FirefoxTry Yahoo Finance on Firefox »
  •  Dow Up1.03% Nasdaq Up1.29%

    Emergent BioSolutions, Inc. (EBS)

    -NYSE
    30.74 Up 1.05(3.54%) May 1, 4:02PM EDT
    Add to Portfolio
    ProfileGet Profile for:
    Emergent BioSolutions, Inc.
    400 Professional Drive
    Gaithersburg, MD 20879
    United States - Map
    Phone: 240-631-3200
    Website: http://www.emergentbiosolutions.com

    Details 
    Index Membership:N/A
    Sector:Healthcare
    Industry:Biotechnology
    Full Time Employees:1,280

    Business Summary 

    Emergent BioSolutions Inc., a specialty pharmaceutical company, develops, manufactures, and commercializes specialized products for use in biodefense and commercial markets in the United States and internationally. The company’s Biodefense segment markets BioThrax, an FDA approved vaccine for the prevention of anthrax disease; BAT (Botulism Antitoxin Heptavalent (A,B,C,D,E,F,G)-Equine) for the treatment of suspected or documented exposure to botulinum neurotoxin A, B, C, D, E, F, or G; Anthrax Immune Globulin Intravenous to treat toxemia associated with inhalational anthrax; Vaccinia Immune Globulin Intravenous for addressing adverse events from smallpox vaccination; and RSDL (reactive skin decontamination lotion) to remove and/or neutralize chemical warfare agents from the skin. This segment is also developing NuThrax, an anthrax vaccine product candidate based on BioThrax combined with CPG 7909, an adjuvant licensed from Pfizer Inc.; and PreviThrax, a recombinant protective antigen anthrax vaccine product candidate, as well as GC-072, the compound in the EV-035 series of broad spectrum antibiotics. Its Biosciences segment markets WinRho SDF, to treat autoimmune platelet disorder and hemolytic disease of the newborn; HepaGam B for the prevention of Hepatitis B reinfection after liver transplantation, and for use as a post-exposure prophylaxis; VARIZIG for post-exposure prophylaxis of chickenpox; and Episil to treat pain associated with oral mucositis. This segment is also developing IXINITY, a therapeutic to prevent bleeding episodes in people with hemophilia B; MOR209/ES414, treatment for metastatic castration resistant prostate cancer; Otlertuzumab, treatment for chronic lymphocytic leukemia. In addition, it provides contract manufacturing services to third-party customers. The company has an agreement with MorphoSys AG to develop and commercialize MOR209/ES414. Emergent BioSolutions Inc. was founded in 1998 and is headquartered in Gaithersburg, Maryland.

    Key Statistics


    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Emergent BioSolutions, Inc.

    Corporate Governance 
    Emergent BioSolutions, Inc.’s ISS Governance QuickScore as of Apr 1, 2015 is 6. The pillar scores are Audit: 1; Board: 6; Shareholder Rights: 10; Compensation: 1.
    Brought to you by Institutional Shareholder Services (ISS)

    Key Executives 
     PayExercised
    Mr. Fuad El-Hibri , 57
    Founder, Exec. Chairman, Chairman of Strategic Operations Committee and Member of Pricing Committee
    889.00K0.00
    Mr. Daniel J. Abdun-Nabi , 60
    Chief Exec. Officer, Pres, Director, Member of Strategic Operations Committee and Member of Pricing Committee
    1.19M119.00K
    Mr. Robert G. Kramer Sr., 58
    Chief Financial Officer, Exec. VP of Corp. Services Division and Treasurer
    667.00K0.00
    Mr. Adam R. Havey , 44
    Exec. VP and Pres of Biodefense Division
    566.00K230.00K
    Mr. Barry A. Labinger , 51
    Exec. VP and Pres of Biosciences Division
    623.00K0.00
    Amounts are as of Dec 31, 2014 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders